Intellectual Property

Intellectual Property

The development work at Cyxone and the research performed by collaborating scientists continues to generate new patent opportunities for the company, and we regularly assess those opportunities.

In order to increase the commercial potential for Rabeximod and its attractiveness to potential partners, we are taking measures to expand its market exclusivity period. A number of additional patent applications have recently been filed, and we will continue exploring more options to further expand our IP platform.

Rabeximod Patents

Patent nameGeographiesExpiration date
Alkyl substituted
indoloquinoxalines
USA, UK, France, Spain, Germany, Sweden, India, China, Mexico, Japan2028 USA
2025 EU and other regions
Patent 2-5 (applied for)TBD2041/ w PE 2043

T20K Patents

Patent nameGeographiesExpiration date
Cyclotides as immunosuppressive agents*USA, Europe, Canada, Australia2032 with +5yr PE

* Patent owned by Medical University of Vienna